How Can We Overcome Tumor Hypoxia in Radiation Therapy?

Journal of Radiation Research

Volumn 52, Issue 5, 2011, Pages 545-556

  Harada, Hiroshi ^a  

^a KYOTO UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOLOGY; DISEASES; RADIATION; TUMORS;

DISTANT METASTASIS; HYPOXIA-INDUCIBLE FACTOR 1; LOCAL RECURRENCE; MICROENVIRONMENTS; RADIATION ONCOLOGISTS; RADIOBIOLOGICAL STUDY; RADIORESISTANCE; TUMOR GROWTH; TUMOR HYPOXIA; TUMOUR CELLS;

RADIOTHERAPY;

MUS;

EID: 80053355093     PISSN: 04493060     EISSN: 13499157     Source Type: Journal    
DOI: 10.1269/jrr.11056     Document Type: Article

References (118)

1. Rontgen WC (1896) On a New Kind of Rays. Science 3: 227-231.
2. Bernier J, Hall EJ and Giaccia A (2004) Radiation oncology: a century of achievements. Nat Rev Cancer 4: 737-747.
3. Brown JM and Wilson WR (2004) Exploiting tumour hypoxia in cancer treatment. Nat Rev Cancer 4: 437-447.
4. Thomlinson RH and Gray LH (1955) The histological structure of some human lung cancers and the possible implications for radiotherapy. Br J Cancer 9: 539-549.
5. Bindra RS, Crosby ME and Glazer PM (2007) Regulation of DNA repair in hypoxic cancer cells. Cancer Metastasis Rev 26: 249-260.
6. Harada H and Hiraoka M (2010) Hypoxia-inducible factor 1 in tumor radioresistance. Current Signal Transduction Therapy 5: 188-196.
7. Moeller BJ, et al (2004) Radiation activates HIF-1 to regulate vascular radiosensitivity in tumors: role of reoxygenation, free radicals, and stress granules. Cancer Cell 5: 429-441.
8. Moeller BJ and Dewhirst MW (2006) HIF-1 and tumour radiosensitivity. Br J Cancer 95: 1-5.
9. Moeller BJ, et al (2005) Pleiotropic effects of HIF-1 blockade on tumor radiosensitivity. Cancer Cell 8: 99-110.
10. Hirst DG (1986) Oxygen delivery to tumors. Int J Radiat Oncol Biol Phys 12: 1271-1277.
11. Elkind MM, et al (1965) Radiation Response of Mammalian Cells Grown in Culture. V. Temperature Dependence of the Repair of X-Ray Damage in Surviving Cells (Aerobic and Hypoxic). Radiat Res 25: 359-376.
12. Suit HD (1968) Application of radiobiologic principles to radiation therapy. Cancer 22: 809-815.
13. Trott KR (1982) Experimental results and clinical implications of the four R's in fractionated radiotherapy. Radiat Environ Biophys 20: 159-170.
14. Mohan R, et al (2000) Radiobiological considerations in the design of fractionation strategies for intensity-modulated radiation therapy of head and neck cancers. Int J Radiat Oncol Biol Phys 46: 619-630.
15. Harada H, Kizaka-Kondoh S and Hiraoka M (2005) Optical imaging of tumor hypoxia and evaluation of efficacy of a hypoxia-targeting drug in living animals. Mol Imaging 4: 182-193.
16. Harada H, et al (2008) Diameter of tumor blood vessels is a good parameter to estimate HIF-1-active regions in solid tumors. Biochem Biophys Res Commun 373: 533-538.
17. Harada H, et al (2009) The Akt/mTOR pathway assures the synthesis of HIF-1alpha protein in a glucose- and reoxygenation-dependent manner in irradiated tumors. J Biol Chem 284: 5332-5342.
18. Harada H, et al (2009) Treatment regimen determines whether an HIF-1 inhibitor enhances or inhibits the effect of radiation therapy. Br J Cancer 100: 747-757.
19. Hanahan D and Weinberg RA (2000) The hallmarks of cancer. Cell 100: 57-70.
20. Vaupel P, Kallinowski F and Okunieff P (1989) Blood flow, oxygen and nutrient supply, and metabolic microenvironment of human tumors: a review. Cancer Res 49: 6449-6465.
21. Hall EJ (1994) Radiobiology for the Radiologists. Fourth Edition, J. B. Lippincott Company, Philadelphia.
22. Brown JM (1979) Evidence for acutely hypoxic cells in mouse tumours, and a possible mechanism of reoxygenation. Br J Radiol 52: 650-656.
23. Dewhirst MW (2009) Relationships between cycling hypoxia, HIF-1, angiogenesis and oxidative stress. Radiat Res 172: 653-665.
24. Dewhirst MW, Cao Y and Moeller B (2008) Cycling hypoxia and free radicals regulate angiogenesis and radiotherapy response. Nat Rev Cancer 8: 425-437.
25. Gray LH, et al (1953) The concentration of oxygen dissolved in tissues at the time of irradiation as a factor in radiotherapy. Br J Radiol 26: 638-648.
26. Kizaka-Kondoh S, et al (2003) Tumor hypoxia: a target for selective cancer therapy. Cancer Sci 94: 1021-1028.
27. Aebersold DM, et al (2001) Expression of hypoxia-inducible factor-1alpha: a novel predictive and prognostic parameter in the radiotherapy of oropharyngeal cancer. Cancer Res 61: 2911-2916.
28. Irie N, Matsuo T and Nagata I (2004) Protocol of radiotherapy for glioblastoma according to the expression of HIF-1. Brain Tumor Pathol 21: 1-6.
29. Ishikawa H, et al (2004) Expression of hypoxic-inducible factor 1alpha predicts metastasis-free survival after radiation therapy alone in stage IIIB cervical squamous cell carcinoma. Int J Radiat Oncol Biol Phys 60: 513-521.
30. Zhang X, et al (2004) Enhancement of hypoxia-induced tumor cell death in vitro and radiation therapy in vivo by use of small interfering RNA targeted to hypoxia-inducible factor-1alpha. Cancer Res 64: 8139-8142.
31. Wang GL, et al (1995) Hypoxia-inducible factor 1 is a basic-helix-loop-helix-PAS heterodimer regulated by cellular O2 tension. Proc Natl Acad Sci USA 92: 5510-5514.
32. Hirota K and Semenza GL (2005) Regulation of hypoxia-inducible factor 1 by prolyl and asparaginyl hydroxylases. Biochem Biophys Res Commun 338: 610-616.
33. Semenza GL (2001) HIF-1, O(2), and the 3 PHDs: how animal cells signal hypoxia to the nucleus. Cell 107: 1-3.
34. Jaakkola P, et al (2001) Targeting of HIF-alpha to the von Hippel-Lindau ubiquitylation complex by O2-regulated prolyl hydroxylation. Science 292: 468-472.
35. Maxwell PH, et al (1999) The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis. Nature 399: 271-275.
36. Chan DA and Giaccia AJ (2007) Hypoxia, gene expression, and metastasis. Cancer Metastasis Rev 26: 333-339.
37. Erler JT, et al (2006) Lysyl oxidase is essential for hypoxia-induced metastasis. Nature 440: 1222-1226.
38. Forsythe JA, et al (1996) Activation of vascular endothelial growth factor gene transcription by hypoxia-inducible factor 1. Mol Cell Biol 16: 4604-4613.
39. Kim JW, Gao P and Dang CV (2007) Effects of hypoxia on tumor metabolism. Cancer Metastasis Rev 26: 291-298.
40. Rofstad EK (2000) Microenvironment-induced cancer metastasis. Int J Radiat Biol 76: 589-605.
41. Liu YV, et al (2007) RACK1 competes with HSP90 for binding to HIF-1alpha and is required for O(2)-independent and HSP90 inhibitor-induced degradation of HIF-1alpha. Mol Cell 25: 207-217.
42. Laughner E, et al (2001) HER2 (neu) signaling increases the rate of hypoxia-inducible factor 1alpha (HIF-1alpha) synthesis: novel mechanism for HIF-1-mediated vascular endothelial growth factor expression. Mol Cell Biol 21: 3995-4004.
43. Zundel W, et al (2000) Loss of PTEN facilitates HIF-1-mediated gene expression. Genes Dev 14: 391-396.
44. Feldser D, et al (1999) Reciprocal positive regulation of hypoxia-inducible factor 1alpha and insulin-like growth factor 2. Cancer Res 59: 3915-3918.
45. Hellwig-Burgel T, et al (1999) Interleukin-1beta and tumor necrosis factor-alpha stimulate DNA binding of hypoxia-inducible factor-1. Blood 94: 1561-1567.
46. Zelzer E, et al (1998) Insulin induces transcription of target genes through the hypoxia-inducible factor HIF-1alpha/ARNT. EMBO J 17: 5085-5094.
47. Zhong H, et al (2000) Modulation of hypoxia-inducible factor 1alpha expression by the epidermal growth factor/phosphatidylinositol 3-kinase/PTEN/AKT/FRAP pathway in human prostate cancer cells: implications for tumor angiogenesis and therapeutics. Cancer Res 60: 1541-1545.
48. Mahon PC, Hirota K and Semenza GL (2001) FIH-1: a novel protein that interacts with HIF-1alpha and VHL to mediate repression of HIF-1 transcriptional activity. Genes Dev 15: 2675-2686.
49. Richard DE, et al (1999) p42/p44 mitogen-activated protein kinases phosphorylate hypoxia-inducible factor 1alpha (HIF-1alpha) and enhance the transcriptional activity of HIF-1. J Biol Chem 274: 32631-32637.
50. Sodhi A, et al (2000) The Kaposi's sarcoma-associated herpes virus G protein-coupled receptor up-regulates vascular endothelial growth factor expression and secretion through mitogen-activated protein kinase and p38 pathways acting on hypoxia-inducible factor 1alpha. Cancer Res 60: 4873-4880.
51. Gorski DH, et al (1999) Blockage of the vascular endothelial growth factor stress response increases the antitumor effects of ionizing radiation. Cancer Res 59: 3374-3378.
52. Zeng L, et al (2008) TS-1 enhances the effect of radiotherapy by suppressing radiation-induced hypoxia-inducible factor-1 activation and inducing endothelial cell apoptosis. Cancer Sci 99: 2327-2335.
53. Li F, et al (2007) Regulation of HIF-1alpha stability through S-nitrosylation. Mol Cell 26: 63-74.
54. Ou G, et al (2009) Usefulness of HIF-1 imaging for determining optimal timing of combining bevacizumab and radiotherapy. Int J Radiat Oncol Biol Phys 75: 463-467.
55. Ljungkvist AS, et al (2000) Changes in tumor hypoxia measured with a double hypoxic marker technique. Int J Radiat Oncol Biol Phys 48: 1529-1538.
56. Bennewith KL and Durand RE (2004) Quantifying transient hypoxia in human tumor xenografts by flow cytometry. Cancer Res 64: 6183-6189.
57. Chaplin DJ, Olive PL and Durand RE (1987) Intermittent blood flow in a murine tumor: radiobiological effects. Cancer Res 47: 597-601.
58. Ljungkvist AS, et al (2007) Dynamics of tumor hypoxia measured with bioreductive hypoxic cell markers. Radiat Res 167: 127-145.
59. Nehmeh SA, et al (2008) Reproducibility of intratumor distribution of (18)F-fluoromisonidazole in head and neck cancer. Int J Radiat Oncol Biol Phys 70: 235-242.
60. Dorie MJ and Kallman RF (1984) Reoxygenation in the RIF-1 tumor. Int J Radiat Oncol Biol Phys 10: 687-693.
61. Murata R, et al (1996) Reoxygenation after single irradiation in rodent tumors of different types and sizes. Int J Radiat Oncol Biol Phys 34: 859-865.
62. Harada H, et al (2007) The combination of hypoxia-response enhancers and an oxygen-dependent proteolytic motif enables real-time imaging of absolute HIF-1 activity in tumor xenografts. Biochem Biophys Res Commun 360: 791-796.
63. Liu J, et al (2005) Real-time imaging of hypoxia-inducible factor-1 activity in tumor xenografts. J Radiat Res (Tokyo) 46: 93-102.
64. Shibata T, et al (1998) Enhancement of gene expression under hypoxic conditions using fragments of the human vascular endothelial growth factor and the erythropoietin genes. Int J Radiat Oncol Biol Phys 42: 913-916.
65. Mueller-Klieser W, et al (1991) Pathophysiological approaches to identifying tumor hypoxia in patients. Radiother Oncol 20 Suppl 1: 21-28.
66. Vaupel P, et al (1991) Oxygenation of human tumors: evaluation of tissue oxygen distribution in breast cancers by computerized O2 tension measurements. Cancer Res 51: 3316-3322.
67. Raleigh JA, et al (1998) Hypoxia and vascular endothelial growth factor expression in human squamous cell carcinomas using pimonidazole as a hypoxia marker. Cancer Res 58: 3765-3768.
68. Lord EM, Harwell L and Koch CJ (1993) Detection of hypoxic cells by monoclonal antibody recognizing 2-nitroimidazole adducts. Cancer Res 53: 5721-5726.
69. Vordermark D and Brown JM (2003) Evaluation of hypoxia-inducible factor-1alpha (HIF-1alpha) as an intrinsic marker of tumor hypoxia in U87 MG human glioblastoma: in vitro and xenograft studies. Int J Radiat Oncol Biol Phys 56: 1184-1193.
70. Loncaster JA, et al (2001) Carbonic anhydrase (CA IX) expression, a potential new intrinsic marker of hypoxia: correlations with tumor oxygen measurements and prognosis in locally advanced carcinoma of the cervix. Cancer Res 61: 6394-6399.
71. Cairns RA, Harris IS and Mak TW (2011) Regulation of cancer cell metabolism. Nat Rev Cancer 11: 85-95.
72. Mankoff DA, et al (2007) Tumor-specific positron emission tomography imaging in patients: [18F] fluorodeoxyglucose and beyond. Clin Cancer Res 13: 3460-3469.
73. Semenza GL (2009) Regulation of cancer cell metabolism by hypoxia-inducible factor 1. Semin Cancer Biol 19: 12-16.
74. Chen C, et al (2001) Regulation of glut1 mRNA by hypoxia-inducible factor-1. Interaction between H-ras and hypoxia. J Biol Chem 276: 9519-9525.
75. Lopez-Lazaro M (2008) The warburg effect: why and how do cancer cells activate glycolysis in the presence of oxygen? Anticancer Agents Med Chem 8: 305-312.
76. Evans SM, et al (2000) Noninvasive detection of tumor hypoxia using the 2-nitroimidazole [18F]EF1. J Nucl Med 41: 327-336.
77. Fujibayashi Y, et al (1997) Copper-62-ATSM: a new hypoxia imaging agent with high membrane permeability and low redox potential. J Nucl Med 38: 1155-1160.
78. Rasey JS, et al (1987) Characterization of radiolabeled fluoromisonidazole as a probe for hypoxic cells. Radiat Res 111: 292-304.
79. Wang K, et al (2009) Modeling acute and chronic hypoxia using serial images of 18F-FMISO PET. Med Phys 36: 4400-4408.
80. Egeland TA, et al (2006) Assessment of fraction of radiobiologically hypoxic cells in human melanoma xenografts by dynamic contrast-enhanced MRI. Magn Reson Med 55: 874-882.
81. Magat J, et al (2010) Noninvasive mapping of spontaneous fluctuations in tumor oxygenation using 19F MRI. Med Phys 37: 5434-5441.
82. Matsumoto S, et al (2010) Imaging cycling tumor hypoxia. Cancer Res 70: 10019-10023.
83. Yasui H, et al (2010) Low-field magnetic resonance imaging to visualize chronic and cycling hypoxia in tumor-bearing mice. Cancer Res 70: 6427-6436.
84. Poskitt TR (1987) Radiation therapy and the role of red blood cell transfusion. Cancer Invest 5: 231-236.
85. Pinel S, et al (2004) Erythropoietin-induced reduction of hypoxia before and during fractionated irradiation contributes to improvement of radioresponse in human glioma xenografts. Int J Radiat Oncol Biol Phys 59: 250-259.
86. Kaanders JH, Bussink J and van der Kogel AJ (2002) ARCON: a novel biology-based approach in radiotherapy. Lancet Oncol 3: 728-737.
87. Coleman CN (1985) Hypoxic cell radiosensitizers: expectations and progress in drug development. Int J Radiat Oncol Biol Phys 11: 323-329.
88. Stratford IJ (1982) Mechanisms of hypoxic cell radiosensitization and the development of new sensitizers. Int J Radiat Oncol Biol Phys 8: 391-398.
89. Minsky BD and Leibel SA (1989) The treatment of hepatic metastases from colorectal cancer with radiation therapy alone or combined with chemotherapy or misonidazole. Cancer Treat Rev 16: 213-219.
90. Simpson JR, et al (1989) Radiation therapy alone or combined with misonidazole in the treatment of locally advanced non-oat cell lung cancer: report of an RTOG prospective randomized trial. Int J Radiat Oncol Biol Phys 16: 1483-1491.
91. Baillet F, et al (1989) Positive clinical experience with misonidazole in brachytherapy and external radiotherapy. Int J Radiat Oncol Biol Phys 16: 1073-1075.
92. Overgaard J, et al (1998) A randomized double-blind phase III study of nimorazole as a hypoxic radiosensitizer of primary radiotherapy in supraglottic larynx and pharynx carcinoma. Results of the Danish Head and Neck Cancer Study (DAHANCA) Protocol 5-85. Radiother Oncol 46: 135-146.
93. Yahiro T, et al (2005) Effects of hypoxic cell radiosensitizer doranidazole (PR-350) on the radioresponse of murine and human tumor cells in vitro and in vivo. J Radiat Res (Tokyo) 46: 363-372.
94. Zeman EM, et al (1986) SR-4233: a new bioreductive agent with high selective toxicity for hypoxic mammalian cells. Int J Radiat Oncol Biol Phys 12: 1239-1242.
95. Baker MA, et al (1988) Metabolism of SR 4233 by Chinese hamster ovary cells: basis of selective hypoxic cytotoxicity. Cancer Res 48: 5947-5952.
96. Zagorevskii D, et al (2003) A mass spectrometry study of tirapazamine and its metabolites. insights into the mechanism of metabolic transformations and the characterization of reaction intermediates. J Am Soc Mass Spectrom 14: 881-892.
97. Peters KB and Brown JM (2002) Tirapazamine: a hypoxia-activated topoisomerase II poison. Cancer Res 62: 5248-5253.
98. Rischin D, et al (2005) Tirapazamine, Cisplatin, and Radiation versus Fluorouracil, Cisplatin, and Radiation in patients with locally advanced head and neck cancer: a randomized phase II trial of the Trans-Tasman Radiation Oncology Group (TROG 98.02). J Clin Oncol 23: 79-87.
99. von Pawel J, et al (2000) Tirapazamine plus cisplatin versus cisplatin in advanced non-small-cell lung cancer: A report of the international CATAPULT I study group. Cisplatin and Tirapazamine in Subjects with Advanced Previously Untreated Non-Small-Cell Lung Tumors. J Clin Oncol 18: 1351-1359.
100. Shin DH, et al (2007) Preclinical evaluation of YC-1, a HIF inhibitor, for the prevention of tumor spreading. Cancer Lett 255: 107-116.
101. Yeo EJ, et al (2003) YC-1: a potential anticancer drug targeting hypoxia-inducible factor 1. J Natl Cancer Inst 95: 516-525.
102. Lee K, et al (2009) Acriflavine inhibits HIF-1 dimerization, tumor growth, and vascularization. Proc Natl Acad Sci USA 106: 17910-17915.
103. Majumder PK, et al (2004) mTOR inhibition reverses Akt-dependent prostate intraepithelial neoplasia through regulation of apoptotic and HIF-1-dependent pathways. Nat Med 10: 594-601.
104. Kim WY, et al (2009) Targeting heat shock protein 90 overrides the resistance of lung cancer cells by blocking radiation-induced stabilization of hypoxia-inducible factor-1alpha. Cancer Res 69: 1624-1632.
105. Oh SH, et al (2007) Structural basis for depletion of heat shock protein 90 client proteins by deguelin. J Natl Cancer Inst 99: 949-961.
106. Dachs GU, et al (1997) Targeting gene expression to hypoxic tumor cells. Nat Med 3: 515-520.
107. Shibata T, Giaccia AJ and Brown JM (2000) Development of a hypoxia-responsive vector for tumor-specific gene therapy. Gene Ther 7: 493-498.
108. Greco O, et al (2003) How to overcome (and exploit) tumor hypoxia for targeted gene therapy. J Cell Physiol 197: 312-325.
109. Liu J, et al (2007) Adenovirus-mediated hypoxia-targeting cytosine deaminase gene therapy enhances radiotherapy in tumour xenografts. Br J Cancer 96: 1871-1878.
110. Ogura M, et al (2005) A tumor-specific gene therapy strategy targeting dysregulation of the VHL/HIF pathway in renal cell carcinomas. Cancer Sci 96: 288-294.
111. Patterson AV, et al (2002) Oxygen-sensitive enzyme-prodrug gene therapy for the eradication of radiation-resistant solid tumours. Gene Ther 9: 946-954.
112. Shibata T, Giaccia AJ and Brown JM (2002) Hypoxia-inducible regulation of a prodrug-activating enzyme for tumor-specific gene therapy. Neoplasia 4: 40-48.
113. Horiot JC, et al (1992) Hyperfractionation versus conventional fractionation in oropharyngeal carcinoma: final analysis of a randomized trial of the EORTC cooperative group of radiotherapy. Radiother Oncol 25: 231-241.
114. Thames HD Jr, et al (1982) Changes in early and late radiation responses with altered dose fractionation: implications for dose-survival relationships. Int J Radiat Oncol Biol Phys 8: 219-226.
115. Yu CX (1995) Intensity-modulated arc therapy with dynamic multileaf collimation: an alternative to tomotherapy. Phys Med Biol 40: 1435-1449.
116. Aoki Y, et al (1987) An integrated radiotherapy treatment system and its clinical application. Radiat Med 5: 131-141.
117. Staffurth J (2010) A review of the clinical evidence for intensity-modulated radiotherapy. Clin Oncol (R Coll Radiol) 22: 643-657.
118. Lecchi M, et al (2008) Current concepts on imaging in radiotherapy. Eur J Nucl Med Mol Imaging 35: 821-837.